Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial -

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions

1599350365534781440

EuroIntervention

In this randomised trial of routine early initiation of PCSK9 inhibitors in patients undergoing primary PCI for STEMI, alirocumab reduced LDL cholesterol by 22% compared with sham control on a background of high-intensity statin therapy. https://t.co/Tz1XqDUQzO https://t.co/Tz1XqDUQzO - view on twitter

See more from EuroIntervention